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SUMMARY 
Transcriptional and chromatin regulations mediate the liver response to nutrient availability.  The role of 
chromatin factors involved in hormonal regulation in response to fasting is not fully understood.  We 
have identified SETDB2, a glucocorticoid-induced putative epigenetic modifier, as a positive regulator 
of GR-mediated gene activation in liver.  Insig2a increases during fasting to limit lipid synthesis, but the 
mechanism of induction is unknown. We show Insig2a induction is GR-SETDB2-dependent. SETDB2 
facilitates GR chromatin enrichment and is key to glucocorticoid dependent enhancer-promoter 
interactions. INSIG2 is a negative regulator of SREBP and acute glucocorticoid treatment decreased 
active SREBP during refeeding or in livers of Ob/Ob mice; both systems of elevated SREBP-1c driven 
lipogenesis. Knockdown of SETDB2 or INSIG2 reversed the inhibition on active SREBPs. Overall, 
these studies identify a GR-SETDB2 regulatory axis of hepatic transcriptional reprogramming and 
identify SETDB2 as potential target for metabolic disorders with aberrant glucocorticoid actions. 
 
INTRODUCTION 
There are fifty SET-domain containing proteins in the human genome and studies over the last decade 
have shown they function as histone methyltransferases and are key players in epigenetic regulatory 
processes (Volkel and Angrand, 2007).  Methyltransferases also have non-histone substrates that 
impact many cellular and metabolic processes (Biggar and Li, 2015; Teperino et al., 2010).   Some of 
these methyltransferases regulate hepatic metabolic homeostasis.  For example, a deficiency in the 
H3K4 methyltransferase MLL3 results in resistance to high fat diet-induced hepatic steatosis (Lee et al., 
2008a). The MLL3 methyltransferase is part of a larger complex that is a selective coactivator for the 
lipogenic transcription factor LXR (Lee et al., 2008b).  Depletion of an arginine methyltransferase, 
PRMT5, was shown to decrease hepatic glucose production. Mechanistically, PRMT5 interacts with the 
co-regulatory factor CRTC2 and the two are recruited to regulatory sites for gluconeogenic genes in 
response to glucagon signaling in the liver (Tsai, 2013). These studies confirm the relevance of protein 
methyltransferases in maintaining liver metabolic homeostasis. However, outside of these few 
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examples, whether any methyltransferases contribute directly to liver physiology is unknown.  
SETDB2 is classified in the KMT1 sub-family of SET domain-containing lysine methyltransferases that 
includes H3K9 methyltransferases such as SUV39H1, G9a and SETDB1. H3K9 methylation is a 
common histone mark associated with gene silencing and recent work in macrophages has linked 
SETDB2 to an antiviral and anti-inflammatory response through negative regulation of LPS and IFNβ-
induced genes (Kroetz et al., 2015; Schliehe et al., 2015). Consistent with it participating in gene 
silencing, a loss of SETDB2 resulted in a decrease in H3K9 trimethylation levels at promoters of 
several proinflammatory genes.   
In contrast, we have identified SETDB2 as a positive regulator of gene expression in the liver and 
reveal a novel underlying regulatory mechanism for glucocorticoid receptor (GR)-mediated gene 
activation during fasting in the liver.  Our mouse liver microarray and RNA-seq analyses comparing 
genes differentially expressed by fasting versus feeding revealed Setdb2 was expressed significantly 
higher in the fasted state among all transcripts encoding SET-domain containing proteins. We show 
SETDB2 gene expression is directly regulated by glucocorticoids and the protein interacts with nuclear 
GR to facilitate long-range GR-dependent chromatin interactions to induce a subset of GR target genes 
during fasting and in response to acute dexamethasone (Dex) challenge.  Interestingly, SETDB2 
recruitment is accompanied by a decrease in H3K9 methylation suggesting this scaffolding role is 
independent of SETDB2 H3K9 methyltransferase activity.  
One of the GR-SETDB2 target genes is Insig2a. The Insig2 gene encodes for two transcripts, Insig2a 
and Insig2b, which differ only in their non-coding first exon. Insig2a, but not Insig2b, was found to 
increase significantly in the liver with fasting and decrease with refeeding (Yabe et al., 2003). The 
mechanism for the induction of Insig2a by fasting however has not been characterized. INSIG2 resides 
at the endoplasmic reticulum trapping the SREBP-SCAP complex to prevent SREBP translocation to 
Golgi (the site of SREBP proteolytic activation).  This regulatory mechanism prohibits nuclear 
translocation and activation of lipogenic genes. Thus, Insig2a induction by GR-SETDB2 contributes to 
the negative regulation of lipogenesis during fasting.  We also show that SETDB2 induces Insig2a in 
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response to an acute glucocorticoid challenge both during the refeeding cycle and in the livers of 
Ob/Ob mice.  In both of these situations, SREBP levels are significantly elevated to increase 
lipogenesis and the glucocorticoid dependent increase in Insig2a results in a decrease in the nuclear 
accumulation of SREBPs.  Thus, our studies link glucocorticoids and GR directly to lipid metabolism 
through SETDB2 and INSIG2.  
RESULTS 
The hepatic transition between the fed and fasted state represents a robust nutritional regulatory switch 
and is dependent on changes in gene expression required to adapt to the two different extreme 
metabolic conditions.  We performed a microarray comparison of genes differentially expressed under 
fasting versus feeding in mouse liver and plotted the data to emphasize genes that were expressed at 
higher levels during fasting (Fig. S1A).  As expected, genes encoding enzymes involved in fatty acid 
oxidation and glucose production were high on the list.  In searching for understudied genes that might 
play key roles in regulating the differential gene patterns we noted that Setdb2, a putative histone H3 
lysine 9 methlytransferase was expressed at increased significantly higher levels during fasting.  This 
was unusual because it was the only putative epigenetic modifying enzyme that exhibited a similar 
pattern of expression.  In support of our finding, Setdb2 was induced by fasting and decreased by 
refeeding in a liver RNA-seq analysis by Zhang et al (Zhang et al., 2011), while transcripts 
corresponding to other SET domain lysine methyltranferases were only moderately altered between 
fasted and refed states (Table S1). SETDB2 is a member of the SET-domain family of lysine 
methyltransferases that have been linked to both positive and negative regulation of gene expression 
(Glaser et al., 2006; Mozzetta et al., 2015). There is abundant literature on many of the SET-domain 
enzymes but comparatively little was known about SETDB2 when we started our work.   
Liver SETDB2 levels increase in response to glucocorticoids  
We first confirmed that Setdb2 mRNA was elevated by gene-specific qPCR and also found nuclear 
SETDB2 protein was elevated in livers of fasted mice compared to a refed state (Fig. 1A). The robust 
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induction of Setdb2 in liver suggested it performs an important regulatory role during fasting. In order to 
evaluate the role of SETDB2 in liver, we sought to first identify the mechanism for elevated Setdb2 
expression during fasting by treating MPH with various compounds that mimic stress-related signals 
that regulate genes relevant to fasting.  These include the fasting hormone glucagon, a catecholamine 
(isoproterenol), a PKA activator (forskolin), a PPAR-α agonist (WY14653), and the synthetic 
glucocorticoid dexamethasone (Dex) (Fig. 1B, S1B-C). Interestingly, Dex was the only compound that 
induced Setdb2 mRNA.  When Dex-treated MPH were exposed to RU486, a GR antagonist, the 
glucocorticoid-mediated increase of Setdb2 was blunted (Fig. S1D). Furthermore, Setdb2 RNA and 
nuclear protein were also robustly increased when ad lib fed mice were injected with Dex. In support of 
these observations, GR knockdown prevented the Setdb2 induction by Dex in mice that were pre-
infected with an adenovirus expressing a sh-GR construct (Fig.1C). We also identified a glucocorticoid 
responsive DNase sensitive region with a GR binding site at -5kb relative to the Setdb2 transcriptional 
start site (TSS) in a previously reported genome-wide analysis of GR binding in the liver (Grontved et 
al., 2013) (Fig. S1E).  Next, we showed that GR was robustly enriched at the predicted site within the 
Setdb2 5’ flanking region in response to either Dex treatment (Fig. S1F) or fasting for 24 hour (Fig. 
S1G). These results are consistent with GR activating Setdb2 expression in liver during fasting or 
following Dex treatment. Nuclear accumulation of the SETDB2 protein in response to elevated 
glucocorticoids parallels the translocation of GR from the cytoplasm to the nucleus (Fig. 1E).  
Therefore, we assessed whether SETDB2 associates with nuclear GR by co-immunoprecipitation (Fig. 
1D), and by confocal immunofluorescence co-localization for nuclear SETDB2 and GR (Fig. 1E), and 
found SETDB2 and GR interact in nucleus in response to glucocorticoid. Thus, we hypothesized that 
SETDB2 may work together with GR to activate glucocorticoid-regulated genes during fasting in the 
liver, which would represent a previously unrecognized GR-SETDB2 stress-responsive axis.   
 
SETDB2 knockdown blunts glucocorticoid-mediated induction of a subset of GR targets  
To evaluate the relevance of the SETDB2-GR interaction, we assessed GR activation of gene 
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expression by Dex in MPH where Setdb2 was knocked down using an sh-adenovirus approach (sh-
DB2).  The sh-DB2 treatment resulted in an 80% knockdown of Setdb2 mRNA. An RNA-seq analysis 
identified 2678 differentially expressed genes in the Dex-treated cells infected with the sh-DB2 
adenovirus relative to the Dex-treated control cells.  The most down-regulated genes in the sh-DB2 
cells corresponded to known Dex-responsive GR targets, such as Tat and Cyp2b10. When we 
compared the SETDB2-regulated genes to GR target genes identified by comparison of wild type and a 
liver knockout of GR (Wong et al., 2010) there were 34 Dex-induced genes that overlapped (36%; 34 of 
the 95) (Fig. 2A). Therefore, a significant set of glucocorticoid-responsive genes is under the control of 
the GR-SETDB2 regulatory axis. 
A list of these putative GR-SETDB2 targets is presented in Table S2 and includes Tat, Cyp2b10, 
Insig2, Igfbp1, and Gdf15, while Dex induction of other known GR targets including Fkbp5, Mt2, and 
Sult1e1 were not affected by SETDB2 knockdown.  To test if this subset of GR targets is also regulated 
by SETDB2 in vivo, we studied the impact of SETDB2 deficiency in mice infected with a sh-control or 
sh-SETDB2 adenovirus followed by Dex treatment.  SETDB2 and GR accumulated in the nucleus in 
response to Dex in the control (Fig. 2B, lanes 1-2), while only GR was detected in the nucleus of sh-
DB2 infected mice (Fig. 2b, lane3). Therefore, SETDB2 knockdown did not impair nuclear accumulation 
of GR, but did compromise Dex induction of Tat and Cyp2b10 (Fig. 2C) as previously observed in MPH. 
Accordingly, GR binding to Tat and Cyp2b10 promoters analyzed by ChIP-qPCR was also decreased 
by SETDB2 knockdown (Fig. 2D).  In contrast, Dex induction of GR targets Mt2 and Sult1e1, which 
were refractory to SETDB2 knockdown in MPH, was also not affected by SETDB2 knockdown (Fig. 
S2A) and GR binding to the promoters of Mt2 and Sult1e1 was also not affected by SETDB2 
knockdown (Fig. S2B). Thus, SETDB2 is required for glucocorticoid-induced GR binding and activation 
of a subset of GR target genes in the liver.  
GR and SETDB2 mediate glucocorticoid-induced transcription of Insig2a via GR binding at the 
Insig2 locus 
Along with Tat and Cyp2b10, Insig2 is also on the list of putative GR-SETDB2 co-regulated genes. This 
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is notable because the INSIG2 protein, which localizes to the endoplasmic reticulum, is a negative 
regulator of SREBP proteolytic activation required for nuclear translocation (Radhakrishnan et al., 
2007).  SREBPs activate genes of lipid synthesis and they are efficiently shut off during fasting in the 
liver.  This is particularly relevant for SREBP-1c, which is a major regulator of insulin-dependent 
lipogenic gene expression, thus, SREBP-1c mRNA and protein levels decline rapidly upon fasting 
(Horton, 1998).  Expression of the Insig2a isoform is specifically induced by fasting (Yabe et al., 2003) 
to limit SREBP maturation as reported over a decade ago, but the mechanism involved has not been 
determined. Based on our results, we hypothesized that GR and SETDB2 co-regulate Insig2a during 
fasting.  Similar to the results for Setdb2, Insig2a expression in MPH was induced by Dex but not by the 
other compounds that mimic stress pathways (Fig. S3A). Additionally, RU486 prevented the Dex-
mediated induction of Insig2a (Fig. S3B).  Insig2a expression was also induced by Dex treatment in 
liver and this was blunted by infection with sh-GR or sh-DB2 (Fig. 3A).  As predicted, sh-GR-DB2 
treatment blunted the fasting dependent induction of Insig2a in the liver (Fig. S3C).  
When we evaluated the Insig2 gene locus within a genome wide data set of Dex-regulated DNase 1 
hypersensitive regions and GR binding in the liver (Grontved et al., 2013), we found both Dex-
responsive DNase 1 hypersensitive sites and GR binding sites near the TSS for Insig2a (Fig. 3B).  
Thus, we performed GR-ChIP using primers to interrogate these sites and showed that GR binding was 
both Dex-responsive and dependent on SETDB2 at 3 sites near the Insig2a TSS (Fig. 3C, S3D, S3E). 
GR enrichment was most robust at the -1.6kb TSS site (Fig. 3C). Interestingly, Dex-responsive 
SETDB2 enrichment was also observed at the -1.6kb site (Fig. 3D), further supporting SETDB2-GR co-
regulation of Insig2a by GR. Additionally, GR and SETDB2 binding were also increased at the Insig2a 
promoter by fasting (Fig. S3F), suggesting that endogenous glucocorticoid action is sufficient to drive 
GR and SETDB2 binding and activation of hepatic Insig2a expression during fasting.  
GR-SETDB2 co-regulation in liver is associated with a decrease in H3K9 methylation 
Our data so far suggest SETDB2 cooperates with GR to activate a specific set of GR target genes in 
response to stress (Fig. 4A-B).  SETDB2 is predicted to be a H3K9 methyltransferase, and its 
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knockdown during interferon stimulation in macrophages results in reduced H3K9me3 at promoters for 
cytokine genes.  Thus, we analyzed H3K9me3 levels at GR-SETDB2 target promoters in livers of Dex-
treated mice.  Surprisingly, H3K9me3 was significantly reduced by Dex treatment at promoters of the 
GR-SETDB2 targets Insig2a, Tat, and Cyp2b10 (Fig. 4C). H3K9me1 (Fig. S4A) and H3K9me2 (Fig. 
S4B) levels were also significantly reduced.  Dex treatment did result in a significant increase in 
H3K4me3 (Fig. 4D). The increase in H3K4me3 along with the decrease in H3K9 methylation are 
consistent with gene activation, but they are inconsistent with SETDB2 acting as a H3K9 
methyltransferase in response to glucocorticoid signaling in the liver. Interestingly, G9a, another 
member of the KMT1 subfamily functions as a molecular scaffold in activation of a subset of GR target 
genes and the scaffold role was not affected by an inhibitor of G9a methlytransferase activity 
(Bittencourt, 2012).  Furthermore, the H3K9 demethylase JMJD1A, participates as a cAMP-induced 
scaffold protein to stimulate enhancer-promoter looping of the Adr1 gene in brown adipose tissue in 
response to catecholamines (Abe et al., 2015) and this bridging function is also independent of the 
demethylase activity of JMJD1A.  Based on these two examples, we hypothesized that SETDB2 might 
regulate GR-dependent enhancer-promoter interactions playing a scaffolding role to activate SETDB2-
GR target genes. 
Long-range chromatin interaction of enhancer-promoter at the Lcn2 locus requires SETDB2 
To test the hypothesis that SETDB2 activates gene expression with GR through chromatin looping, we 
used the 3C (capturing chromatin conformation) method (Dekker, 2002) focusing on Lcn2. Previous 
studies described long-range chromatin interactions at the Lcn2 gene locus that participate in Lcn2 
activation by glucocorticoids in a cell culture model (Hakim et al., 2009).  In liver, Dex robustly 
increased Lcn2 expression and this induction was significantly blunted when SETDB2 was knocked 
down (Fig. 5A). GR and SETDB2 both associated with the Lcn2 promoter, and GR enrichment was 
dependent on SETDB2 (Fig. 5B). Therefore, we used Lcn2 to test our hypothesis that SETDB2 
facilitates GR-dependent chromatin looping to activate target gene expression. The proposed 
mechanism for the strong activation of Lcn2 expression by glucocorticoids involves long-range 
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chromatin interactions between an enhancer site near the neighboring Ciz1 gene and a GRE site within 
the Lcn2 proximal promoter (Hakim et al., 2009).  We noted there is a Dex responsive DNase 1 site at 
+26kb relative to the Lcn2 TSS which is close to the previously reported enhancer region for Lcn2 in 
cell lines (Hakim et al., 2009). We measured GR binding by ChIP-qPCR at this enhancer site and found 
GR enrichment was SETDB2 dependent (Fig. 5C). RAD21 is a component of the Cohesin complex and 
is known to participate in chromatin looping (Mishiro et al., 2009). We found RAD21 was significantly 
enriched at the Lcn2 promoter in response to Dex and this enrichment was also significantly reduced by 
SETDB2 knockdown (Fig. 5D). 
Next, we evaluated interactions between the Lcn2 promoter/enhancer using chromatin from livers of 
mice treated with Dex. This revealed a Dex-dependent increase in association of chromatin from the 
+26kb region with the TSS site. Furthermore, this putative looping decreased significantly in mice 
containing a hypomorphic gene trap construct (DB2GT, Fig. S5A) inserted at position 59423974 of 
Chromosome 14 upstream of exon6 in the SETDB2 gene (Fig. 5E). SETDB2 gene expression was 
significantly reduced in livers of the SETDB2 gene trap mice (DB2GT) (Fig. S5B) and Lcn2 induction in 
response to Dex was also blunted (Fig. S5B). Taken together, these results suggest SETDB2 acts as a 
scaffold protein to facilitate long-range enhancer-promoter interactions required for activation of a 
subset of GR target genes.   
To further evaluate the role of SETDB2 in the Dex-dependent long range chromatin looping, we 
crossed the DB2GT mouse with a mouse expressing the FLP recombinase which results in excision of 
the gene trapped construct and leaves a floxed allele at the otherwise wild type gene locus (Fig. S5A).  
Endogenous expression of Setdb2 and Lcn2 was rescued by this approach (Fig. S5C), in addition to 
the enhancer-promoter interaction observed at the Lcn2 locus by 3C-qPCR (Fig. 5F).  Binding of GR, 
SETDB2, and RAD21 to the Lcn2 promoter and GR binding at the Lcn2 enhancer were also restored 
(Fig. S5D).  
Long-range enhancer-promoter at the Insig2 locus requires SETDB2 
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In order to determine whether the SETDB2-dependent looping is a more general mechanism, we also 
evaluated long-range interactions within the Insig2a locus. A Dex-responsive DNase hypersensitive site 
was identified in the Insig2a locus at +41kb from the TSS in a previous data set (Grontved et al., 2013). 
Similar to Lcn2, GR binding to this site was SETDB2-dependent (Fig. 6A). We also detected a Dex-
dependent enhancer RNA (eRNA) transcribed from the +41kb site which was dependent on both 
SETDB2 and GR (Fig. S6A). Interestingly, the +41kb eRNA also increased robustly in the fasted state 
(Fig. S6B), which was accompanied by GR and SETDB2 enrichment at this enhancer (Fig. S6C). 3C-
qPCR analyses of livers revealed a Dex-responsive long-range interaction between the +38/+48kb 
region with the Insig2a TSS that was SETDB2 dependent (Fig. 6B), 
Similar to what was observed for Lcn2, mating of the SETDB2 gene-trap mice with the FLP expresser 
rescued the blunted induction of Insig2a expression (Fig. S6D) and restored GR and SETDB2 binding 
(Fig. S6E). These experiments demonstrate that hepatic SETDB2 is required for maximum 
glucocorticoid induction of a select group of GR targets, including Insig2a and Lcn2, where the 
presence of SETDB2 facilitates long-range chromatin interactions between a distal enhancer and the 
gene proximal promoter.  
SETDB2 mediates Dex dependent SREBP regulation through Insig2a  
INSIG2 is a negative regulator of SREBP maturation and conditions that result in an increase in INSIG 
levels are predicted to decrease nuclear accumulation of SREBPs (Jeon and Osborne, 2012).  This 
occurs in liver during fasting through the increased expression of Insig2a; however, SREBP-1c gene 
expression is also suppressed rapidly by fasting because of the acute decrease in insulin.  So whether 
the glucocorticoid dependent induction of Insig2 expression would be sufficient to decrease nuclear 
SREBP levels was unclear because of the rapid loss in SREBP-1c gene expression upon fasting.  
Thus, we evaluated SREBP expression in mice that were refed following a fast where SREBP levels 
are robustly induced.  Two hours prior refeeding, we treated mice with a vehicle control or Dex, food 
was then added back and all mice were sacrificed after 8 hour of refeeding.  The nuclear levels of both 
SREBP-1 and SREBP-2 were very low in mice harvested immediately following 24 hours of fasting and, 
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as expected, both were significantly increased by refeeding (Fig. 7A, lanes 5-9).  Interestingly, Dex 
treatment at the time of refeeding significantly reduced the induction of both SREBPs (Fig. 7A, lanes 
10-14).  The acute Dex effect on SREBP processing is also concentration-dependent with SREBP-1 
appearing to be more sensitive (Fig. S7). Parallel to the inhibition of SREBP processing, the Dex 
treatment resulted in accumulation of membrane bound INSIG2 protein, which is consistent with our 
model and would result in the retention of the SCAP-SREBP complex in the endoplasmic reticulum to 
prevent SREBP nuclear accumulation.  
To further evaluate the mechanism, we repeated this experiment but we also pre-infected cohorts of 
mice with sh-adenoviruses for SETDB2 or INSIG2 (Fig. 7B) and probed their roles in blunting SREBP 
regulation.  Knockdown of either INSIG2 or SETDB2 resulted in decreased INSIG2 protein at the 
membrane and both blunted the Dex inhibition of SREBP accumulation. These results demonstrate that 
SETDB2 is required to mediate the acute Dex effect on nuclear SREBP.  They also demonstrate that 
SETDB2 is upstream of INSIG2 because whereas knockdown of SETDB2 reduced both SETDB2 and 
INSIG2, knockdown of INSIG2 restored SREBP but SETDB2 expression was not affected.  
Dex-dependent activation of Insig2a reduces SREBP-1 levels in livers of Ob/Ob mice 
In addition to their obesity, Ob/Ob mice accumulate excess hepatic triacylglycerol (TAG) which is 
mediated through an elevated level of SREBP-1 and an increase in de novo lipogenesis (Shimomura, 
1999).  When Ob/Ob mice were crossed with SREBP-1c knockout mice, the accumulation of liver TAG 
was significantly reduced without an effect on body weight (Yahagi et al., 2002).  Thus, increased 
hepatic SREBP-1c is a key driver of fatty liver in the Ob/Ob mouse.  Ob/Ob mice also have elevated 
circulating glucocorticoids but reduced levels of hepatic 11-β hydroxysteroid dehydrogenase (11β-
HSD), an enzyme responsible for the local production of active corticosterone from inactive 11-keto 
forms (Liu, 2003).  Additionally, expression of TAT, a sensitive GR target gene is also significantly 
reduced in Ob/Ob (Blake, 1970a; Blake, 1970b).  Thus, we predicted Ob/Ob mice might exhibit partial 
hepatic glucocorticoid resistance and this might contribute to elevated levels of SREBP-1c and excess 
TAG accumulation.  Indeed, upon treating Ob/Ob mice with Dex, INSIG2 levels were increased and this 
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was accompanied by a significant decrease in the very high levels of nuclear SREBP-1c (Fig. 7C).  This 
highlights the importance of the GR-SETDB2 axis in hepatic glucocorticoid regulation 
DISCUSSION 
The mammalian liver has evolved and integrated metabolic network to help maintain whole body 
energy homeostasis.  It is a dynamic and robust process and incudes mechanisms to adapt rapidly to 
regulatory signals that change in response to fluctuations in nutrient demand and availability. A failure 
of the system leads to metabolic diseases ranging from simple NAFLD to steatohepatitis or NASH. 
Glucocorticoids play an important role in liver metabolism in part through local glucocorticoid receptor 
(GR) signaling. In the current study, we uncovered a new GR-associated protein, called SETDB2, that 
modulates glucocorticoid-responsiveness of a select subset of GR target genes, which includes Insig2, 
an important negative regulator of SREBP and lipid metabolism (Radhakrishnan et al., 2007). Yabe et 
al. originally reported that INSIG2 was encoded by two mRNAs with distinct 5’ terminal non-coding 
exons expressed from two different promoters (Yabe et al., 2003). The upstream promoter drives 
expression of the Insig2a isoform, which Yabe et al. showed was inducible by fasting in the liver 
whereas Insig2b is constitutively expressed from the second promoter.  The mechanism for fasting-
induced expression from the Insig2a promoter and whether it plays a key role in regulating SREBP 
levels has not been established.  We show that Insig2a induction during fasting is strongly dependent 
on the combined actions of GR and SETDB2.   
There is abundant literature on a number of SET domain lysine methyltransferases contributing to 
cellular signaling pathways, but comparatively little is known about the physiological and biochemical 
functions of SETDB2 in liver (Alam et al., 2015; Mozzetta et al., 2015).  SETDB2 is a member of the 
KMT1 family of SET domain containing lysine methyltransferases that includes SUV39H1, G9a, and 
SETDB1 (Volkel and Angrand, 2007). The similarity in primary structure of SETDB2 and SETDB1 has 
led to the assumption that SETDB2 is a H3K9 methyltransferase, but evidence is lacking.  A study by 
the Gozani lab showed SETDB1, but not SETDB2, is capable of transferring a chemical label to the H3 
tail peptide consistent with H3K9 methyltransferase activity for SETDB1 but not SETDB2 (Binda et al., 
  14 
2011).  Another study found SETDB2 displayed no methylation activity with the unmodified or the H3K9 
monomethylated peptide substrates (Falandry et al., 2010), but the authors noted a weak SETDB2 
methylation activity when the H3K9 dimethylated peptide was used as a substrate. SETDB2 and 
SETDB1 share only 36% sequence identity in their active site SET domains which are bifurcated and 
have distinct inserted sequences this and other sequence differences between these proteins is 
consistent with their distinct epigenetic roles. 
 
Two recent studies have shown that SETDB2 is induced by interferon signaling in macrophages in the 
context of acute respiratory viral infection (Kroetz et al., 2015; Schliehe et al., 2015). In this setting, 
SETDB2 loss of function experiments suggest it is induced to turn off a select set of pro-inflammatory 
and anti-viral genes during the resolution phase of the initial proinflammatory response.  Cytokine gene 
expression remained high and H3K9me3 at the corresponding gene promoters was lower during the 
resolution phase in SETDB2-deficient macrophages. Thus, it is interesting that our liver studies show 
glucocorticoids induce SETDB2 recruitment to hepatic chromatin along with GR, and this is associated 
with gene activation.  Additionally, the co-enrichment of GR and SETDB2 to target gene loci in liver was 
accompanied by a decrease in H3K9me3, which is the predicted enzyme mark for SETDB2.  Levels of 
H3K9me1 and H3K9me2 were also reduced.  This is a consistent pattern for H3K9me changes that 
accompany gene activation and suggests the putative H3K9me3 activity of SETDB2 is not involved in 
co-enrichment and activation with GR.  Recent studies have found epigenetic modifiers can positively 
and negatively contribute to gene expression programming in a context-dependent manner.  For 
example, G9a, known for its H3K9me2 activity in gene silencing, also acts as a positive transcriptional 
coregulator for GR and estrogen receptor (ERα) in cancer cells (Bittencourt, 2012; Zhang et al., 2016). 
G9a can dimethylate a non-histone substrate, the estrogen receptor (ERα), creating a docking site for 
an epigenetic reader (PHF20 tudor domain) for the recruitment of the MOF acetyltransferase complex 
to cancer-associated ER-responsive promoters (Zhang et al., 2016). Similar to G9a, SETDB2-mediated 
activation of gene targets may involve methylation of non-histone substrates and current experiments 
are aimed at identifying SETDB2 methylation targets.   
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Overall, our studies suggest SETDB2 is important to drive the transcriptional activation of genes 
relevant to the metabolic stress of fasting in liver, a condition when circulating glucocorticoids are 
elevated. Therefore, we predicted that altered SETDB2 levels in the liver could affect metabolic 
homeostasis through deregulated expression of GR-SETDB2 targets, such as Insig2a. This is notable 
because INSIG2 can inhibit lipogenesis via retention of the inactive SCAP-SREBP complex within the 
ER membrane.  We therefore evaluated the impact of glucocorticoid-induced hepatic Insig2a 
expression on SREBP processing during the fasting to refeeding transition.  During fasting, SREBPs 
are very low in part due to INSIG2, while refeeding inhibits Insig2a expression and drives SREBP 
nuclear accumulation to activate the lipogenic and cholesterogenic gene programs.  When we injected 
Dex into mice just before the refeeding phase was initiated, the levels of INSIG2 protein were 
maintained at a high level and SREBP nuclear accumulation was dramatically reduced. This suggests 
that acute Dex treatment in vivo leads to a SETDB2/GR-mediated induction of hepatic Insig2a and an 
increase in membrane INSIG2 protein that effectively inhibits SREBP nuclear translocation. When this 
was repeated under conditions where either INSIG2 or SETDB2 protein levels were knocked down, 
there was a blunting of the Dex inhibition of SREBP accumulation. Interestingly, the knockdown 
experiments also demonstrate that SETDB2 is upstream of INSIG2 because while knockdown of either 
one resulted in partial restoration of SREBP, the knockdown of INSIG2 restored SREBP but SETDB2 
levels were unaffected.   
Insufficient activation of Insig2a through GR signaling may be an important contributor to NAFLD in 
Ob/Ob mice.  SREBP-1c levels are elevated in livers of Ob/Ob mice (Shimomura, 1999) and likely 
contribute to hepatic steatosis in this model because when the SREBP-1c knockout mouse was 
crossed with Ob/Ob, body weight remained high but hepatic triglyceride levels were significantly 
reduced (Yahagi et al., 2002). This apparent hepatic glucocorticoid resistance is also supported by the 
significant reduction in expression and activity of 11β-HSD1 (Liu, 2003) and TAT in Ob/Ob liver (Blake, 
1970b).  11β-HSD1 produces locally active corticosterone from the inactive 11-dehydrocorticosterone in 
order to amplify local glucocorticoid action. Mice deficient in 11β-HSD1 have a blunted induction of 
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glucocorticoid-induced genes in liver during fasting, while SREBP targets are increased in the refed 
state (Kotelevtsev, 1997; Morton et al., 2001). Thus, we posited that liver SREBP-1c levels in Ob/Ob 
mice might be elevated in part because of ineffective regulation of Insig2a by GR.  Consistent with this 
hypothesis, when we injected Dex into Ob/Ob mice, there was an increase in membrane localized 
INSIG2 in the liver that was matched by a reciprocal decline in the excessively high SREBP-1c nuclear 
protein levels.   
Mechanistically, we showed that SETDB2 influences chromatin looping at the Lcn2 and Insig2 loci. This 
occurs through dynamic enhancer-promoter interactions that increase in response to glucocorticoids, 
and decrease with deficiencies in either SETDB2 or GR. We found a previously undocumented 
enhancer-promoter interaction between a +41kb enhancer and the proximal TSS of Insig2.  The +41kb 
enhancer site coincides with a Dex-responsive DNase hypersensitive region in liver (Grontved et al., 
2013) that we show expresses a Dex-responsive and SETDB2 dependent eRNA that is also induced by 
fasting. DNase hypersensitive sites and eRNA are both markers for active enhancers and they are 
associated with chromatin looping as reported previously in an estrogen responsive system (Hah et al., 
2013). Epigenetic modifiers, like SETDB2, have previously been reported to contribute to chromatin 
looping-mediated gene regulation independent of their enzymatic activity, as is the case for G9a and 
JMJD1A (Abe et al., 2015; Bittencourt, 2012). G9a was described as a molecular scaffold for 
transcriptional coactivators in an alveolar epithelial carcinoma cell line, a function which was maintained 
in the presence of an inhibitor of G9a methylation activity (Bittencourt, 2012). JMJD1A is an H3K9 
demethylase that regulates expression of a subset of gene targets within the beta-adrenergic system of 
brown adipose. JMJD1A facilitates chromatin looping that is dependent on cAMP phosphorylation of 
JMJD1A. However, a JMJD1A mutation that eliminates its demethylase activity did not affect its role in 
looping (Abe et al., 2015). Like G9A and JMJD1A, we demonstrate SETDB2 works as a putative 
molecular scaffold to dynamically regulate signal dependent long-range enhancer-promoter 
interactions.   The scaffold function for SETDB2 in chromatin looping is relevant to activation of stress-
responsive GR targets within the liver. The fasting-related GR-cistrome in liver is clustered with other 
transcription factor motifs within open chromatin domains and is predicted to confer a rapid induction of 
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stress-responsive genes (Goldstein and Hager, 2015), like Insig2a.  Thus, future work will evaluate if 
the synergy between GR and other transcription factors relies on SETDB2 to facilitate looping and 
regulate expression of fasting-induced genes in liver.     
In summary, we have uncovered a novel function for SETDB2 as a GR-interacting protein that is both 
glucocorticoid-responsive at the transcriptional level and is co-enriched at the protein level along with 
GR at select glucocorticoid regulated target sites. This provides mechanistic insight into GR’s mode of 
action for transcriptional regulation in liver and makes SETDB2 a potential therapeutic target to 
modulate glucocorticoid action in metabolic diseases associated with altered glucocorticoid sensitivity 
such as obesity and diabetes, or in patients undergoing chronic glucocorticoid treatment. These 
conditions are associated with liver dysfunction and can lead to NAFLD, NASH, fibrosis or liver cancer 
(Ahmed et al., 2012; Kadmiel and Cidlowski, 2013; Quax et al., 2013; Rose et al., 2010). Finally, 
SETDB2 is also induced by Dex in other metabolic tissues such as white adipose and muscle (data not 
shown).  Thus, SETDB2 may contribute to a wide array of GR-associated diseases, which increases 
the disease relevance and therapeutic potential for targeting SETDB2 action.   
EXPERIMENTAL PROCEDURES 
Animals and treatments 
All animal experiments were performed in accordance with accepted standards of animal welfare and 
with permission of the Sanford-Burnham-Prebys Medical Research Institute Lake Nona International 
Animal Care and Use Committee (protocol 2012-0088). We used 8 to 12-week-old male C57BL/6J 
mice from the Jackson Laboratory and maintained them on a chow diet (Teklad Diets, #2016) with a 
12-hour light (7AM-7PM), 12-hour dark cycle (7PM-7AM). For fasting and refeeding studies, mice were 
sacrificed after a 24-hour fast (7AM-7AM), or after a 24-hour fast followed by either 2 hour refeeding 
(ChIP and 3C analysis) or 8-hour refeeding (protein analysis). Equal amounts of total liver RNA pooled 
from 6 mice per group (24 hour fasted versus fed) were used for triplicate microarray analysis as 
previously described (Shin et al., 2012). Dexamethasone (Dex) (Steraloids Inc., P0519-000) was 
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delivered intraperitoneally at a dose of 10mg/kg, food was removed at the time of injection, and tissues 
were harvested 4 hours after treatment for RNA analysis or 2 hours for ChIP and 3C analysis. In 
refeeding studies, Dex was delivered 1 hour prior to refeeding. For adenoviral-mediated gene 
knockdown studies, adenovirus overexpressing short-hairpin (sh) Control, shSETDB2, shGR (Lemke et 
al., 2008), or shINSIG2 constructs (Haas et al., 2012) were delivered by intravenous retro-orbital 
injections at a dose of 2x109  plaque forming units (PFU) per mouse seven days prior to harvest.   
Setdb2tm1a mice containing a hypomorphic gene trap construct inserted at nucleotide position 59423974 
of Chromosome 14, upstream of exon6 of SETDB2, were created from an embryonic stem (ES) cell 
clone EPD0164_4_E09 (JM8.N4 C57BL/6N) obtained from the Knockout Mouse Project (KOMP) 
repository. Germ line transmission of the Setdb2tm1a allele was achieved by breeding male chimeric 
mice with C57BL/6J females and confirmed by genotyping along with the presence of black-coat pups. 
Setdb2tm1a mice were bred with FLPeR mice (Jackson Laboratory, stock no. 009086) to excise the gene 
trap construct and result in the Setdb2flox conditional allele with loxP sites flanking exon 6 of the Setdb2 
locus. 
Chromosome Conformation Capture (3C) analysis 
3C-qPCR analysis of mouse liver was performed as described previously (Hagege et al., 2007) with 
minor modifications.  Liver (1.0 gram) was minced and fixed with 1% formaldehyde for 10min, treated 
with 125 mM glycine/PBS for 5 min, and washed with PBS. Liver pellets were processed as described 
above in the ChIP assay section in order to obtain intact nuclei. Nuclei were lysed in CutSmart 
Digestion buffer (NEB) containing 0.3% SDS for 1 hour at 37°C while shaking at 900rpm followed by 
addition of 2% Triton X-100 (final concentration) and continued incubation at 37°C for 1 hour. The 
chromatin DNA was then subject to restriction endonuclease digestion by addition of 400U of restriction 
enzyme (Hind III for Lcn2 gene locus analysis or EcoR1 for Insig2 analysis). After overnight enzymatic 
digestion, chromatin samples were adjusted to 1.6% SDS and incubated at 65°C for 20 min. Sample 
buffers were adjusted to a ligation buffer composition as described in Hagehe et al., 2007 in a total 
volume of 6.125 mL containing 1% Triton-X100 (final concentration) followed by 1-hour incubation at 
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37°C. Chromatin fragments were ligated for 5 hours at 16°C and maintained at room temperature for 30 
min prior to addition of proteinase K and overnight incubation at 65°C. Samples were treated with 
Riboshredder RNAse (Epicentre) for 45 minutes followed by phenol-chloroform DNA purification. Re-
ligated fragments were further purified with the Roche High Pure PCR production purification kit and the 
resulting 3C template DNA was adjusted to 100 ng/uL. Standard curves were prepared using GAPDH 
for reference and promoter-enhancer interactions were assessed by TaqMan real-time quantitative 
PCR. Bacterial artificial chromosome (BAC) clone RP23-61N22 (CHORI BacPac Resource Center) 
spanning the Ciz1-Lcn2 locus, and a BAC clone RP23-260H4 (CHORI BacPac Resource Center) 
spanning the Insig2 locus were used to prepare the control template for normalization of relative PCR 
amplification efficiencies. Primers and TaqMan probe sequences are provided in supplemental material. 
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FIGURE LEGENDS 
 
Figure 1. SETDB2 is a glucocorticoid responsive gene. (A) Liver Setdb2 mRNA and SETDB2 
nuclear immunoblot in refed versus fasted liver. (B) Setdb2 mRNA in mouse primary hepatocytes 
treated with various stress/fasting-related compounds. (C) Liver Setdb2 induction by DEX is GR 
dependent. (D) GR and SETDB2 interact in MPH. (E) SETDB2 and GR immunofluorescence in Hepa1-
6. *p<0.05 relative to control, (n=4-6).; RF=Refed, F=Fast, DB2=SETDB2. Data are represented as 
mean ± SEM. 
 
Figure 2. SETDB2 is required for Dex-mediated activation of select GR targets. A) Pie chart of 
SETDB2-GR co-regulated genes. B) SETDB2 immunoblot of liver nuclear protein and mRNA in mice 
infected with shControl (shCtrl) or shSETDB2 (shDB2) adenovirus. Liver mRNA and GR-ChIP qPCR at 
promoters of C) Tat and D) Cyp2b10. n=3. Groups with different letters are statistically different, 
p<0.05. Data are represented as mean ± SEM. 
 
Figure 3. SETDB2 and GR are required for Dex-mediated activation of Insig2a. A) Liver Insig2a 
mRNA from mice infected with Ad-shControl (shCtrl), shSETDB2 (shDB2), shGR in presence or 
absence of Dex. B) Insig2 gene track showing Dex-responsive DNase and GR binding site at -
1.6kbTSS. C) GR ChIP-qPCR and D) SETDB2 ChIP-qPCR at Insig2a promoter. Groups with different 
letter are statistically different (p<0.05). Data are represented as mean ± SEM. 
 
Figure 4. SETDB2 does not correlate with H3K9methylation at promoters of Dex-induced GR 
targets. ChIP-qPCR at promoters of SETDB2-GR regulated genes. A) GR B) SETDB2 C) H3K9me3 D) 
H3K4me3. *p<0.05 relative to vehicle treatment. Data are represented as mean ± SEM. 
 
Figure 5. Long range chromatin interaction of enhancer-promoter at Lcn2. A) Liver Lcn2 mRNA. 
  27 
B) GR and SETDB2 ChIP-qPCR at Lcn2 promoter. C) GR-ChIP qPCR at Lcn2 enhancer. D) RAD21-
ChIP qPCR at Lcn2 promoter. E) 3C-qPCR at Lcn2 locus from wild type (WT) and SETDB2-deficient 
mouse livers (DB2GT) +/- DEX. F) 3C-qPCR at Lcn2 locus from mouse liver with restored SETDB2 
(DB2FLP) in presence of Dex. Groups with different letter are statistically different (p<0.05). *p<0.05 
versus control. Bait for 3C-qPCR spans Lcn2 promoter from TSS to -1.5kbTSS. Data are represented 
as mean ± SEM. 
 
Figure 6. Long range chromatin interaction of enhancer-promoter at Insig2. A) GR and SETDB2 
ChIP-qPCR at Insig2 enhancer in livers lacking SETDB2 or GR. B) 3C qPCR at Insig2 locus from wild 
type and SETDB2 gene trap mouse livers +/- DEX. *p<0.05 relative to sh-Control+PBS or WT PBS. 
Bait for 3C-qPCR spans Insig2a promoter from TSS to -8kbTSS. Data are represented as mean ± 
SEM. 
 
Figure 7. Dex inhibition of SREBP processing during refeeding.  A) Liver immunoblot of nuclear 
SREBP1/2, during a fasted or refed state +/- Dex. B) Liver immunoblot during refed state +/-DEX in 
mice infected with shControl (shCtrl), shSetdb2 (shDB2), shInsig2. n= pool 3 mice. C) Dex inhibition of 
SREBP processing in Ob/Ob liver. N-Nuclear, M-Membrane. Each lane in Figs. 7A and 7C represents 
protein from individual mice.  
 
 
